Company intelligence / Profile preview
Tharimmune, Inc.
- Ownership
- Public · THAR
- Employees
- ~3
- Development stage
- Phase 2
Overview
Tharimmune’s lead asset, TH104, has shown the ability to suppress chronic debilitating pruritus associated with primary biliary cholangitis—a rare orphan liver disease with no known cure. The company’s early-stage pipeline includes novel multi-specific antibodies targeting validated oncology targets such as PD‑1, HER2 and HER3 using advanced antibody discovery platforms.[1][2][5]
- Therapeutic areas
- GastroenterologyOncologyDermatology
- Modalities
- Small molecules (TH104)Multi-specific antibodies (preclinical pipeline)Biologics (via collaborations and licenses)
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $139.9M
- Total revenue
- $1.5M
- Enterprise value
- $102.7M
Beyond the preview
Go deeper on Tharimmune, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tharimmune, Inc..